Literature DB >> 10861932

Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions.

M A Bowen1, A A Aruffo, J Bajorath.   

Abstract

CD6 is a cell surface receptor belonging to the scavenger receptor cysteine-rich (SRCR) protein superfamily (SRCRSF). It specifically binds activated leukocyte cell adhesion molecule (ALCAM, CD166), a member of the immunoglobulin (Ig) superfamily (IgSF). CD166 was among the first molecules identified as a ligand for an SRCRSF receptor, and the CD6-CD166 interaction was the first interaction characterized involving SRCRSF and IgSF proteins. We focus here on what has been learned about the specifics of the CD6-CD166 interaction from in vitro analysis. The studies are thought to provide an instructive example for the analysis of interactions between single-path transmembrane cell surface proteins. Using soluble recombinant forms, the extracellular binding domains of receptor and ligand have been identified and characterized in a variety of assay systems. Both CD6 and CD166 have been subjected to intense mutagenesis and monoclonal antibody (mAb) binding studies and residues critical for their interaction have been identified. The availability of structural prototypes of both superfamilies has made it possible to map the binding site in CD166 and, more recently, in CD6 and compare these regions to epitopes of mAbs that block, or do not block, the interaction. In addition, the molecular basis of observed cross-species receptor-ligand interactions could be rationalized. These studies illustrate the value of structural templates for the interpretation of sequence and mutagenesis analyses. Proteins 2000;40:420-428. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861932

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  16 in total

Review 1.  CD5, an important regulator of lymphocyte selection and immune tolerance.

Authors:  Chander Raman
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Alcama mediates Edn1 signaling during zebrafish cartilage morphogenesis.

Authors:  Priya Choudhry; Deepa Joshi; Birgit Funke; Nikolaus Trede
Journal:  Dev Biol       Date:  2010-11-10       Impact factor: 3.582

3.  Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.

Authors:  Linlin Xu; Khalid S Mohammad; Hao Wu; Colin Crean; Bradley Poteat; Yinghua Cheng; Angelo A Cardoso; Christophe Machal; Helmut Hanenberg; Rafat Abonour; Melissa A Kacena; John Chirgwin; Attaya Suvannasankha; Edward F Srour
Journal:  Cancer Res       Date:  2016-09-07       Impact factor: 12.701

4.  Clinical implications of activated leukocyte cell adhesion molecule expression in breast cancer.

Authors:  Daxun Piao; Tao Jiang; Gavin Liu; Baosheng Wang; Jin Xu; Anlong Zhu
Journal:  Mol Biol Rep       Date:  2011-06-14       Impact factor: 2.316

5.  ALCAM is indirectly modulated by miR-125b in MCF7 cells.

Authors:  H Begum Akman; S Duygu Selcuklu; Mark T A Donoghue; Shiva Akhavantabasi; Aysegul Sapmaz; Charles Spillane; M Cengiz Yakicier; A Elif Erson-Bensan
Journal:  Tumour Biol       Date:  2014-12-25

6.  The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome.

Authors:  Jorge Vera; Rafael Fenutría; Olga Cañadas; Maite Figueras; Rubén Mota; Maria-Rosa Sarrias; David L Williams; Cristina Casals; José Yelamos; Francisco Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-13       Impact factor: 11.205

7.  Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.

Authors:  M Burkhardt; E Mayordomo; K-J Winzer; F Fritzsche; T Gansukh; S Pahl; W Weichert; C Denkert; H Guski; M Dietel; G Kristiansen
Journal:  J Clin Pathol       Date:  2006-02-16       Impact factor: 3.411

8.  Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.

Authors:  Ruby Alonso-Ramirez; Séverine Loisel; Caroline Buors; Jacques-Olivier Pers; Enrique Montero; Pierre Youinou; Yves Renaudineau
Journal:  Arthritis       Date:  2011-02-10

9.  CD166 Engagement Augments Mouse and Human Hematopoietic Progenitor Function via Activation of Stemness and Cell Cycle Pathways.

Authors:  Jing Zhang; Joydeep Ghosh; Safa F Mohamad; Chi Zhang; Xinxin Huang; Maegan L Capitano; Andrea M Gunawan; Scott Cooper; Bin Guo; Qingchun Cai; Hal E Broxmeyer; Edward F Srour
Journal:  Stem Cells       Date:  2019-08-14       Impact factor: 5.845

10.  CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action.

Authors:  Lee I Garner; Andrew Hartland; Johannes Breuning; Marion H Brown
Journal:  Immunology       Date:  2018-06-13       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.